Optimal Usage of Sacubitril/Valsartan For Heart Failure Treatment In Canada Potentially Reduces Mortality, Hospitalizations And Early Discharge Re-Admissions

The objective was to quantify the number of deaths, HF hospitalizations, and 30-day HF re-admissions that potentially could be avoided with optimal usage of sac/val for the treatment of HFrEF patients in Canada.

Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: P Haddad, RS McKelvie Source Type: research